Shots:
- Health Canada has approved Kisqali (ribociclib) + an aromatase inhibitor (AI) for adj. treatment of adults with HR+/HER2-, stage II-III early breast cancer (EBC) at high risk of recurrence
- Approval was supported by global P-III (NATALEE) study assessing Kisqali + AI vs AI alone as an adj. treatment of pts (n=5101) with stage II & III HR+/HER2- EBC
- Trial showed significant & meaningful reduction in risk of disease recurrence, with a 25.1% relative reduction in invasive disease-free survival events among stage II & III EBC pts at final analysis
Ref: Novartis | Image: Novartis| Press Release
Related News:- Processa Pharmaceuticals and Intact Therapeutics Enter Binding Term Sheet for PCS12852 Licensing Deal
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
